Kolkata: The stocks of Bombay Dyeing, Aditya Birla Capital, Divi’s Laboratories, KEC International, Gland Pharma are expected to be in the news today (February 4) on account of their Q3 FY25 results. Both market indices BSE Sensex and Nifty fell on February 3. Sensex climbed down 319.22 points or 0.41% to end the day’s trade at 77,186.74 points while Nifty ended the trading session at 23,361.05 points, down 121.10 points, or 0.52%.
Market analysts think the RBI’s decision on whether to cut key policy rate (like the Repo rate), Q3 results of diffirent companies, FII investment flows and global cues could be the major factors to influence the benchmark indices BSE Sensex and Nifty. The fallout of the Budget 2025 could continue to be felt as well.
Bombay Dyeing & Manufacturing Company Q3 results
Nusli Wadia-controlled Bombay Dyeing & Manufacturing Company reported Q3 FY25 results on February 3, when it was seen that the company reported a 12.6% rise in revenue from operations for Q3 FY25 — its sales touched Rs 414.8 crore, up from Rs 369.2 crore in the same quarter of FY24. The company returned to positive EBITDA of Rs 15.9 crore against a loss of Rs 24.2 crore in Q3 of last year. EBITDA (operating profit) margin was recorded at 3.8% despite market challenges.
Aditya Birla Capital Q3 results
Aditya Birla Capital on February 3, 2025 reported a net profit of Rs 708 crore during the Q3 period of FY25, which indicated a decline of 3.77% compared to the figure of Rs 735.76 crore during the same quarter last year. Net Interest Income was at Rs 1876 crore, up 7.2% (y-o-y) and the revenue from operations was at Rs 9,381.35 crore — up 9.28% against Rs 8,584.50 crore recorded in Q3 FY24. The overall lending portfolio of the NBFC and housing finance operations, rose 27% (y-o-y) and 6% on a sequential basis to touch Rs 1,46,151 crore at the end of Q3 FY25. The total AUM of AMC, life insurance and health insurance business grew by 23% (y-o-y) and stood at Rs 5,03,377 crore in Q3 FY25.
Divi’s Laboratories Q3 results
API (active pharmaceutical ingredients) manufacturer Divi’s Laboratories reported 64.52% jump in net profits to reach Rs 589 crore in Q# FY25. It was at Rs 358 crore in Q3 FY24. The revenue from operations of the company surged 25% to touch Rs 2,319 crore in Q3 FY25 which was at Rs 1,855 crore in the same period lats year. EBITDA leaped 52% to Rs 743 crore in the October-December period as against Rs 489 crore in Q3 last year and EBITDA margin was at 32% vs 26.4% in the same period in FY24.
KEC International Q3 results
KEC International on February 3 reported a 33.8% (y-o-y) jump in net profit which was recorded at Rs 129.6 crore for the Q3 in FY25. In the same quarter last year it posted a net profit of Rs 96.9 crore. Revenue from operations rose 6.8% to reach Rs 5,349.4 crore against R5,006.7 crore in Q3 FY24. EBITDA (operating profit) rose 21.6% to touch Rs 374.4 crore in Q3 Fy25 against Rs 307.9 crore in Q3 FY24.
Gland Pharma Q3 results
On February 3, Gland Pharma announced its financial results for Q3 FY25 period. Net profit for the October-December period rose 7% (y-o-y) ton reach Rs 205 crore, while revenue from operations dipped 10% (y-o-y) to Rs 1,384 crore. The total income of the company dropped to Rs 1,443 crore, while the total expenses went down to Rs 1,143 crore.
(Disclaimer: This article is only meant to provide information. News9 does not recommend buying or selling shares or subscriptions of any IPO, Mutual Funds and crypto assets.)
Both market indices BSE Sensex and Nifty fell on February 3. Sensex climbed down 319.22 points or 0.41% to end the day’s trade at 77,186.74 points while Nifty ended the trading session at 23,361.05 points, down 121.10 points, or 0.52%. The shares of Bombay Dyeing, Aditya Birla Capital, Divi’s Laboratories, KEC International, Gland Pharma should be in the news due to their Q3 FY25 financial. Markets Business News – Personal Finance News, Share Market News, BSE/NSE News, Stock Exchange News Today
